Show simple item record

dc.contributor.authorSelker, H. P.
dc.contributor.authorEichler, H.-G.
dc.contributor.authorStockbridge, N. L.
dc.contributor.authorMehta, C. R.
dc.contributor.authorKaitin, K. I.
dc.contributor.authorMcElwee, N. E.
dc.contributor.authorHonig, P. K.
dc.contributor.authorErban, J. K.
dc.contributor.authorD’Agostino, R. B.
dc.contributor.authorOye, Kenneth A.
dc.date.accessioned2015-03-25T15:42:41Z
dc.date.available2015-03-25T15:42:41Z
dc.date.issued2013-09
dc.date.submitted2013-08
dc.identifier.issn0009-9236
dc.identifier.issn1532-6535
dc.identifier.urihttp://hdl.handle.net/1721.1/96173
dc.description.abstractWe propose an “efficacy-to-effectiveness” (E2E) clinical trial design, in which an effectiveness trial would commence seamlessly upon completion of the efficacy trial. Efficacy trials use inclusion/exclusion criteria to produce relatively homogeneous samples of participants with the target condition, conducted in settings that foster adherence to rigorous clinical protocols. Effectiveness trials use inclusion/exclusion criteria that generate heterogeneous samples that are more similar to the general patient spectrum, conducted in more varied settings, with protocols that approximate typical clinical care. In E2E trials, results from the efficacy trial component would be used to design the effectiveness trial component, to confirm and/or discern associations between clinical characteristics and treatment effects in typical care, and potentially to test new hypotheses. An E2E approach may improve the evidentiary basis for selecting treatments, expand understanding of the effectiveness of treatments in subgroups with particular clinical features, and foster incorporation of effectiveness information into regulatory processes.en_US
dc.description.sponsorshipNational Center for Research Resources (U.S.) (Grant UL1 RR025752)en_US
dc.description.sponsorshipNational Center for Advancing Translational Sciences (U.S.) (Grant UL1 TR000073)en_US
dc.language.isoen_US
dc.publisherWiley Blackwellen_US
dc.relation.isversionofhttp://dx.doi.org/10.1038/clpt.2013.177en_US
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs 3.0 Licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/en_US
dc.sourceNatureen_US
dc.titleA Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trialsen_US
dc.typeArticleen_US
dc.identifier.citationSelker, H P, K A Oye, H-G Eichler, N L Stockbridge, C R Mehta, K I Kaitin, N E McElwee, P K Honig, J K Erban, and R B D’Agostino. “A Proposal for Integrated Efficacy-to-Effectiveness (E2E) Clinical Trials.” Clinical Pharmacology & Therapeutics 95, no. 2 (September 23, 2013): 147–153.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Political Scienceen_US
dc.contributor.departmentMassachusetts Institute of Technology. Engineering Systems Divisionen_US
dc.contributor.mitauthorOye, Kenneth A.en_US
dc.relation.journalClinical Pharmacology & Therapeuticsen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsSelker, H P; Oye, K A; Eichler, H-G; Stockbridge, N L; Mehta, C R; Kaitin, K I; McElwee, N E; Honig, P K; Erban, J K; D’Agostino, R Ben_US
dc.identifier.orcidhttps://orcid.org/0000-0002-9811-8415
mit.licensePUBLISHER_CCen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record